Plus Therapeutics, Inc. (PSTV)

Over the past six months, Plus Therapeutics, Inc.'s stock price has been impacted by several events. The share price declined by 62.91% over the past year. The company received Medicare enrollment approval for its CNSide Diagnostic and secured Blue Shield of California coverage for its CNSide® Cerebrospinal Fluid Assay. Plus Therapeutics initiated manufacturing activities with SpectronRx for REYOBIQ™ and regained compliance with the Nasdaq minimum bid price requirement. The company presented positive interim data for REYOBIQ™ and the U.S. FDA granted Orphan Drug Designation to REYOBIQ™. Shareholder dilution was identified as a new major risk.

Information explicitly detailing demand seasonality for Plus Therapeutics, Inc.'s products and services is not readily available. The demand for their products is likely driven by clinical trial progress, regulatory milestones, and the prevalence of the specific rare and difficult-to-treat cancers they target, rather than typical seasonal consumer patterns. For their diagnostic service, CNSide®, demand would be tied to the diagnosis and management of CNS metastases, which is generally not seasonal.

Plus Therapeutics, Inc. is a U.S. clinical-stage pharmaceutical company in the Healthcare sector, focusing on Biotechnology and Pharmaceuticals. The company develops targeted radiotherapeutics and diagnostic services for difficult-to-treat cancers of the brain and central nervous system (CNS). Its major product candidates include REYOBIQ™ (rhenium Re186 obisbemeda), an investigational liposomal radiopharmaceutical; CNSide®, a molecular diagnostic service; and 188RNL-BAM, being developed to treat various solid organ cancers.

Plus Therapeutics, Inc. is headquartered in Houston, Texas, U.S. The company also maintains additional laboratories and state-of-the-art clean rooms in Houston for key development, manufacturing, and preclinical activities.

Plus Therapeutics' brand reputation has been positively influenced by positive clinical trial results for REYOBIQ™, regulatory approvals and designations, expanded coverage for CNSide®, and manufacturing advancements. The presentation of positive interim data for REYOBIQ™ has bolstered the company's reputation. The U.S. FDA granting Orphan Drug Designation to REYOBIQ™ is a significant positive. Securing Medicare enrollment approval and Blue Shield of California coverage for the CNSide® diagnostic assay has enhanced the company's standing. Initiating manufacturing activities for REYOBIQ™ indicates progress towards commercialization.

Approximately 57.48% of Plus Therapeutics' stock is owned by Institutional Investors, 15.39% by Insiders, and 27.13% by Public Companies and Individual Investors. Major institutional owners include Vanguard Capital Management Llc, Vanguard Group Inc, L1 Global Manager Pty Ltd, and BlackRock, Inc.